The apolipoprotein E (APOE) E4 allele and stroke increase the risk of cognitive decline. However, the association of the APOE E4 allele before and after stroke is not well understood.
A ccumulating evidence suggests that dementia is largely attributed to mixed vascular and neurodegenerative pathologies. 1 Specifically, stroke is a major risk factor for cognitive impairment that may lead to vascular dementia, [2] [3] [4] which also increases the risk of mortality. [5] [6] [7] However, about 10% of patients experience a stroke event after dementia. 8 This increased risk is also observed among participants with poor cognitive function. 9 The apolipoprotein E (APOE) E4 allele in old age is associated with an increased accumulation of b amyloid 10, 11 that leads to greater risk of Alzheimer's disease and dementia. [12] [13] [14] [15] [16] [17] [18] Some studies have investigated the association of the APOE E4 allele with dementia as a consequence of stroke. 2, 19, 20 Having one or more copies of the APOE E4 allele increased the risk of dementia among participants with no history of stroke. However, the risk of dementia did not increase with the occurrence of stroke. 2 The risk of dementia was higher among those with stroke and without the APOE E4 allele. 19 However, this risk did not increase with the APOE E4 allele. 20 In a genome-wide association study, a weak association was found between the APOE E4 allele and stroke, 21 and at least 1 study showed an association with cerebral infarcts, the pathologic substrate of clinical stroke. 22 The APOE E4 allele also increased the risk of mortality. [23] [24] [25] However, it is not clear whether cognitive function and stroke may explain this risk.
The APOE e4 allele is associated with increased cognitive decline, and dementia may occur after stroke. Hence, it is important to understand the interplay of APOE e4 allele and stroke on cognitive decline and mortality. The goal of this paper is to examine the following research questions: (1) whether the increase in cognitive decline before and after stroke is similar between participants with and without the APOE E4 allele, (2) if the APOE E4 allele is associated with incident stroke after adjusting for cognitive function, and (3) whether the APOE E4 allele is associated with mortality after adjusting for cognitive function and stroke.
METHODS

Study Design and Participants
The Chicago Health and Aging Project (CHAP) was performed using a door-to-door census of 4 neighborhoods in south side of Chicago during 1993 to 2012. Genotyping was performed on a sample of participants described previously in greater detail. 26 Cognitive function tests were conducted during in-home interviews in B3-year cycles. A total of 4807 participants were genotyped and eligible for this investigation. Of the 4807 participants, 668 were excluded for incomplete Medicare coverage, 337 had a single cognitive assessment, 347 had stroke at baseline, and 11 had missing health or demographic variables and excluded from our study. This resulted in an analytical sample of 3444 participants.
Participants excluded for a single cognitive assessment or prevalent stroke had significantly lower baseline cognitive function than participants included in the study (P < 0.0001). However, we found no significant difference in baseline cognitive function between participants with incomplete Medicare coverage and our analytic sample (P = 0.48).
Cognitive Function
We created a composite cognitive function test score based on a short battery of 4 tests that included 2 tests of episodic memory (Immediate and Delayed Recall Story) derived from the East Boston Test 27, 28 ; 1 test of perceptual speed (Symbol Digits Modalities Test) 29 and another test of general orientation and global cognition (Mini-Mental State Examination). 30 The composite cognitive function test score was created by averaging the 4 tests after centering and scaling each to their baseline mean and SD. This construct explains about 75% variation in the individual cognitive test scores and has shown good validity and reliability. 31 Change in composite test scores can be interpreted as the change in SD units relative to the baseline assessment of the study cohort.
Mortality
Mortality was ascertained by field reports from study interviewers. Following field reports of death, personal identifiers were matched with the Social Security Administration Death Master File. Once the match was made, personal identifiers were then linked to the National Death Index (NDI) for uniform ascertainment and nosology. In our sample, uniform ascertainment and verification of mortality using NDI was completed through 12/31/2010. Of the 1457 deceased participants, NDI reports were confirmed for 1274 (87%) participants; an additional 132 (9%) participants have been identified as deceased after January 1, 2011, but are waiting to be confirmed following a forthcoming updated NDI database. The remaining 51 (4%) unconfirmed deaths were reported either during in-home visits or in Medicare records but could not be confirmed from NDI due to a lack of personal identifiers.
Stroke Hospitalizations
All CHAP participants were aged 65 years or older, and most participants had coverage through the Center for Medicare and Medicaid Services. When participants were actively involved in a health maintenance organization, they were excluded from our analysis, since they would not simultaneously be enrolled in Medicare during those periods. In this study, participants were enrolled in Medicare 86% of the time and in an health maintenance organization 14% of the time. Prevalent stroke cases were ascertained at baseline using stroke hospitalization data as well as the selfreported question "Have you ever been told by a doctor, nurse or therapist that you had a stroke or brain hemorrhage?" with "Yes" and "Suspect or possible" as a positive response in 347 participants, who were excluded from our analysis. For this study, we coded 2 types of strokes, ischemic strokes identified by ICD-9 codes 433.01, 433. , and 438.0, and hemorrhagic strokes identified by ICD-9 codes 430, 431, 432.1, and 432.9. These codes were validated by coauthor (N.T.A.), who is a board-certified neurologist and CHAP investigator. 32 A validity study was performed by comparing magnetic resonance imaging (MRI) data available in a subsample of our population with the stroke hospitalization data. In this subsample, participants with a stroke diagnosis also had one or more infarcts on about 90% of cases. About 18% of participants with no stroke diagnosis had one or more infarcts on MRI-most were small infarcts, suggesting that subclinical cerebrovascular disease was present that did not amount to a stroke hospitalization.
APOE e4 Allele
The APOE genotypes were ascertained using 2 single nucleotide polymorphisms (SNPs): rs7412 and rs429358 using the methods described by Hixson and Vernier 33 based on the primers described by Wenham et al 34 These SNPs were genotyped in each subject using the Sequenom hME Mas-sARRAY platform. The genotyping success rate was nearly 100% for both the SNPs, which were also in Hardy-Weinberg equilibrium. In this study, 1034 (30%) participants had 1 copy of the APOE E4 allele and 122 (4%) had 2 copies of the APOE E4 allele. In previous studies, the APOE E4 allele was associated with higher risk for AD and cognitive decline. 14, 15, 35 Because of the small sample size in E4 homozygote, we combined E4 homozygote with heterozygote.
Health and Demographic Variables
Our analysis adjusted for demographic variables, including age (centered at 75 y), sex (males or females), race (African Americans or non-Hispanic Whites), and education (measured in number of years of schooling completed and centered at 12 y). These covariates were selected since they may modify the association between cognitive decline and APOE E4 allele status. For stroke and mortality risk models, we adjusted for health and lifestyle measures, including body mass index (kg/m 2 ), heart disease, diabetes, systolic blood pressure, diastolic blood pressure, smoking status (former smoker and current smokers vs. never smoker), physical activities (total minutes of walking, jogging, yard work, dancing, calisthenics or general exercise) and daily alcohol consumption (grams of alcohol per day) in addition to demographic variables.
Statistical Analysis
Descriptive statistics were computed using means, SDs for continuous variables, and percentages for categorical variables. We also compared participant characteristics by the APOE E4 allele using 2-sample independent t tests and w 2 tests depending on the measurement type. We modeled cognitive decline and mortality using a joint modeling framework with a longitudinal model for cognitive decline and a time-to-event model for mortality. 36 The longitudinal model for cognitive decline was based on a linear spline with time-of-stroke hospitalization as a change point to examine cognitive decline before and after incident stroke within a random effects model. 37 This was accomplished by creating a new time measure-difference in time between incident stroke hospitalization and time at assessments after incident stroke. Among participants with no incident stroke, this measure would be 0. A linear contrast was used to combine the additive components of prestroke cognitive decline and relative increase in poststroke cognitive decline to provide an estimate of the absolute change in poststroke cognitive decline. Random effects were included for the intercept and slopes. Given that 31% of participants with incident stroke died during the observation period, it was imperative that we accounted for mortality using a time-to-event model to account for truncation by estimating the parameters of the longitudinal model and time-to-mortality model within a shared parameter model framework. In addition, we used time-dependent Cox models to examine the association of the APOE E4 allele with incident stroke while adjusting for cognitive function assessments prior to incident stroke. Joint models were fitted using JM library and time-dependent Cox models using survival library in R program. 38 
RESULTS
Population Characteristics
Demographic and health characteristics of the sample by the APOE E4 allele are shown in Table 1 . Participants were 66% African Americans and 61% females with an average age of 71.9 years, and education of 12.6 years.
During follow-up, 505 (15%) participants were hospitalized for stroke. The average follow-up time was 9.8 years for those with stroke and 9.4 years for those without stroke. Of the 505 participants with incident stroke, 156 (31%) had died without a follow-up, thereby only contributing to mortality risk model. Also, baseline cognitive function was lower among participants who died without a follow-up compared to participants who had one or more follow-ups (0.176 vs. 0.277; P = 0.001). The average follow-up time was 4.5 years after stroke hospitalization. We found no significant difference in follow-up time after stroke by the APOE E4 allele. Participants with the APOE E4 allele had a lower baseline cognitive function than those without the APOE E4 allele. Table 2 shows the risk of time-to-incident stroke in terms of cognitive function, the APOE E4 allele, and demographic, health, and lifestyle measures. Poor cognitive function was associated with an increased risk of incident stroke [hazard ratio (HR) = 1.41, 95% confidence interval (CI), 1.25-1.58]. However, the APOE E4 allele was not associated with incident stroke (HR = 1.04, 95% CI, 0.86-1.26). Older age, systolic blood pressure, heart disease, diabetes, and current smoking status were also associated with an increased risk of incident stroke.
Association of Cognitive Function and the APOE e4 Allele With Incident Stroke
Association of the APOE e4 Allele and Incident Stroke With Cognitive Decline
The annual change in cognitive function by incident stroke and the presence of the APOE E4 allele is shown in Table 3 . Among participants without stroke, the presence of the APOE E4 allele was associated with increased Among participants with incident stroke and no copies of the APOE E4 allele, cognitive decline before incident stroke was 0.039 units/year among, which increased to 0.115 units/ year following incident stroke. Therefore, cognitive decline was roughly 2.3 fold faster following incident stroke among participants with no copies of the APOE E4 allele (P < 0.0001). This increase was similar to the increase observed due to the APOE E4 allele among participants free of stroke.
Among participants with incident stroke and one or more copies of the APOE E4 allele, cognitive decline before incident stroke was 0.091 units/year, which showed a small but nonsignificant increase to 0.102 units/year (P = 0.26). Therefore, incident stroke did not increase the rate of cognitive decline among participants with one or more copies of the APOE E4 allele. The 10-year course of cognitive decline before and after incident stroke among participants with and without the APOE E4 allele is shown in Figures 1A and B , respectively.
From our regression models, age and education were associated with cognitive decline after incident stroke among those without the APOE E4 allele (data not shown). However, demographic variables were not associated with cognitive decline among those with the APOE E4 allele. A test for racial differences in the association of cognitive decline and APOE E4 allele was not significant (P = 0.74).
Association of Cognitive Function, Stroke, and the APOE e4 Allele With Mortality
Poor cognitive function was associated with a higher risk of mortality (HR = 2.04, 95% CI, 1.89-2.19) ( Table 4 ). The APOE E4 allele (HR = 1.16, 95% CI, 1.03-1.30) and incident stroke (HR = 1.26, 95% CI, 1.10-1.43) were also associated with higher risk of mortality. In a separate model, a 2-way interaction of the APOE E4 allele and incident stroke on mortality was not significant (P = 0.53). A significant interaction of age with cognitive function (P = 0.012) and incident stroke (P = 0.032) on increased mortality risk was also observed, suggesting that age played an important role in mortality risk (data not shown).
DISCUSSION
Our findings suggest that the APOE E4 allele was not associated with incident stroke in old age. However, poor cognitive function was associated with incident stroke.
Although the presence of the APOE E4 allele was associated with faster cognitive decline, incident stroke did not increase cognitive decline among participants with the E4 allele. In addition, incident stroke increased cognitive decline by over 2 fold among participants without the E4 allele. These findings suggest that the association of incident stroke and cognitive decline is different by the presence of the APOE E4 allele. Poor cognitive function, the APOE E4 allele, and stroke all contributed to increased risk of mortality.
Increased cognitive decline before incident stroke suggests subclinical or silent cerebrovascular disease, which may result in incident stroke irrespective of the presence of the APOE E4 allele. Participants probably had low cognitive reserve and greater cognitive impairment resulting in a nonsignificant association with cognitive decline among those with the APOE E4 allele. However, participants without the APOE E4 allele had incident stroke from risk factors that were not associated with cognitive decline. Hence, our findings suggest that these participants had a pattern of cognitive decline before stroke that was similar to those without stroke. After incident stroke, participants showed increased cognitive decline that was slightly higher than those with the APOE E4 allele. Additional MRI-based studies to assess the presence of subcortical or lacunar infarcts, or microhemorrhages and their association to cognitive function are needed to examine these possibilities in greater detail.
Poor cognitive function may be indicative of preexisting subclinical cerebrovascular disease, which may explain why cognitive function was associated with an increased risk of stroke, 9 while the APOE E4 allele was not associated with stroke. An earlier meta-analysis that did not adjust for cognitive function found a marginal association of the APOE E4 allele with ischemic stroke. 21 Our population-based study found that the APOE E4 allele was not associated stroke after adjusting for cognitive function.
The APOE E4 allele and stroke increased mortality risk even after controlling for other known risk factors. Interestingly, even after adjusting for known health and biological risk factors, poor cognitive function was still associated with mortality risk. Further studies examining the possible genetic pathways of the APOE E4 allele, cognition, and vascular disease might provide a better understanding of mortality risk in old age.
The primary strengths of this study are the prospective study design with uniform ascertainment of biological, lifestyle and health characteristics, and cognitive function. Participants were drawn from a large geographically defined biracial population, making it likely that a broad spectrum of participants and paths of cognitive changes were represented. Cognitive function was assessed using four validated scales and measured on >2 occasions among those at risk of incident stroke. Almost 57% of older adults died during the follow-up period leading to informative censoring as well as providing sufficient power to detect robust mortality-adjusted findings. Cognitive decline and stroke both uniquely contribute to neurological and cerebrovascular health with independent and overlapping etiologies in the aging process. The APOE E4 allele was directly genotyped in a large population-based sample of 3444, which is a much larger sample than previous studies that have reported the association of incident dementia and stroke relative to the APOE E4 allele.
Several limitations of our study also need to be addressed. One of the main limitations of this study is the assessment of incident stroke using Medicare data with external validation in a much smaller sample. As such, minor or silent stroke events could not be accounted for in our investigation. It is likely that the study included participants who had stroke but were not characterized as such in Medicare records. Also, participants may be incorrectly coded as having stroke hospitalization or other insurance coverage not reported to the Medicare database. These misclassification errors may alter the sizes of our cognitive decline estimates. Even though time-of-stroke was collected from actual Medicare dates, cognitive assessments around this time may be at a maximum of 3 years away. Therefore, any short-term changes following stroke may be difficult to ascertain.
In addition, about 31% of participants did not provide cognitive assessments after incident stroke. Although these participants had a lower baseline cognitive function, their cognitive decline before stroke was similar to those who provided follow-up data. Even though no race differences between African Americans and Whites were observed for cognitive decline before and after incident stroke among APOE carriers, and given the small number of stroke events, our ability to detect these changes may be limited. Cardiovascular disease markers may also modify the association of APOE E4 allele with incident stroke and cognitive decline. However, our sample is not large enough to reliably test these moderating effects.
The APOE E4 allele was not associated with stroke but was associated with mortality and more rapid cognitive decline before incident stroke. However, incident stroke was associated with faster cognitive decline that was more severe in participants without the APOE E4 allele. The trajectory of cognitive decline after stroke had minor changes among participants with the APOE E4 allele suggesting two possibilities. First, that this subgroup of participants was not severely affected by an incident stroke event, or secondly that the group that had the worst decline was already deceased. As such, understanding the role of the APOE E4 allele and stroke on cognitive decline and mortality might help us better understand the underlying disease mechanism and create better preventive strategies. 
